Telik's TRAP Drug Discovery Technology Surpasses 3 Million Molecular Fingerprint Milestone

Telik, Inc. has announced that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related Affinity Profiling (TRAP(R)). TRAP technology exploits the principle that drugs act by adhering to and interacting with key cellular proteins.

Telik has developed a computational approach to determine a molecular fingerprint for each compound in its library. TRAP technology uses these molecular fingerprints to search the library for promising lead molecules and to optimize these structures into new drug candidates.

TRAP also allows the use of a wide range of biologically relevant assays. Several applications of the technology were recently described at the 99th annual meeting of the American Association for Cancer Research.

"This milestone is the latest achievement as we advance Telik's TRAP technology," said Robert Lum, Ph.D., Telik's Vice President of Technology and Preclinical Development. "This library of computational molecular fingerprints, combined with our proprietary data mining algorithms, will help drive the continued growth of Telik's pipeline of preclinical candidates."

TRAP technology has been the focus of several industry partnerships and collaborations with leading academic cancer centers. Telik continues to seek additional TRAP-based partnerships with corporations and academic investigators for the discovery and development of novel therapeutics.